-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Joint Scientific and Education Program Symposia on Barriers to Successful Clinical Trial Design & Accrual - Live Q&A

PhD Trainee
Program: Scientific Symposia
Hematology Disease Topics & Pathways:
Clinical Trials, Workforce, Diversity, Equity, and Inclusion (DEI)
Saturday, December 11, 2021: 4:00 PM-4:45 PM
B405-B407, Level 4, Building B (Georgia World Congress Center)
Co-chairs:
Alan E. Mast, MD, PhD, Blood Center of Wisconsin and Grzegorz S. Nowakowski, MD, Mayo Clinic
Disclosures:
Mast: Vega Therapeutics: Honoraria; Novo Nordisk: Honoraria, Research Funding. Nowakowski: Karyopharm Therapeutics: Consultancy; Celgene/Bristol Myers Squibb: Consultancy, Research Funding; Ryvu Therapeutics: Consultancy; Roche: Consultancy, Research Funding; Curis: Consultancy; Bantham Pharmaceutical: Consultancy; Daiichi Sankyo: Consultancy; Zai Labolatory: Consultancy; Kyte Pharma: Consultancy; Kymera Therapeutics: Consultancy; Genentech: Consultancy, Research Funding; MorphoSys: Consultancy; Incyte: Consultancy; Selvita: Consultancy; TG Therapeutics: Consultancy; Blueprint Medicines: Consultancy; Nanostrings: Research Funding.
Panelists:
Thomas E. Witzig, MD, Mayo Clinic , Nadine J. Barrett, PhD, MS, MA, Duke University, Duke University School of Medicine , Barbara E. Bierer, MD, Brigham and Women's Hospital and Mark Winderlich, PhD, Morphosys, MorphoSys Inc.
Disclosures:
Witzig: Karyopharm Therapeutics, Celgene/BMS, Incyte, Epizyme: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene/BMS, Acerta Pharma, Kura Oncology, Acrotech Biopharma, Karyopharm Therapeutics: Research Funding. Bierer: Johnson and Johnson: Consultancy, Research Funding; Clinithink: Membership on an entity's Board of Directors or advisory committees; Eli Lilly & Co: Consultancy; Q State: Membership on an entity's Board of Directors or advisory committees; Voyager Therapeutics: Membership on an entity's Board of Directors or advisory committees. Winderlich: MorphoSys: Current Employment, Current equity holder in publicly-traded company, Current holder of stock options in a privately-held company, Patents & Royalties: Patents.
This session will address barriers to successful clinical trial design and accrual through the lens of diversity, equity and inclusion. The session is meant to address study design strategies that should be improved in the context of DEI; discuss the role socioeconomic barriers play in patient enrollment; and provide tools on how to address implicit bias in clinical research.
See more of: Scientific Symposia